{
    "patient": {
        "Name": "Monica Nichols",
        "DateOfBirth": "1958-05-25",
        "Sex": "Male",
        "Diagnosis": "Follicular thyroid cancer",
        "BodyPart": "Thyroid",
        "Physician": "Dr. David Williams",
        "TreatingInstitution": "Hughes Group"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Thyroid",
            "CollectedDate": "2024-04-09",
            "ReceivedDate": "2024-04-10",
            "TumorPercentage": "53%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2024-04-11",
            "ReceivedDate": "2024-04-11"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Frameshift-LOF",
                "VariantAlleleFraction": "1.91%"
            },
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Stopgain-LOF",
                "VariantAlleleFraction": "19.48%"
            },
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": " p.W266* Nonsense-LOF",
                "VariantAlleleFraction": "25.86%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "SMO",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": " p.W266* Nonsense-GOF",
                "VariantAlleleFraction": "19.68%"
            },
            {
                "Gene": "FLT3",
                "DNA Alteration": "c.2028C>A",
                "GeneMutation": "p.D835X Spliceregionvariant-LOF",
                "VariantAlleleFraction": "18.03%"
            },
            {
                "Gene": "HSD3B1",
                "DNA Alteration": "c.1100C>A",
                "GeneMutation": "p.T367N Nonsense-GOF",
                "VariantAlleleFraction": "10.09%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": []
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "27 m/Mb",
            "Tmbpercentile": "43%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "FBXW7",
                "DNA Alteration": "c.1394G>A",
                "GeneMutation": "p.R465H Nonsense-LOF",
                "VariantAlleleFraction": "4.36%"
            },
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G751A Frameshift-LOF",
                "VariantAlleleFraction": "3.51%"
            },
            {
                "Gene": "KRAS",
                "DNA Alteration": "c.39C>A",
                "GeneMutation": "p.G12L Stopgain-LOF",
                "VariantAlleleFraction": "5.6%"
            },
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Spliceregionvariant-GOF",
                "VariantAlleleFraction": "8.22%"
            },
            {
                "Gene": "SDHD",
                "DNA Alteration": "c.34G>A",
                "GeneMutation": "p.G12S Nonsense-LOF",
                "VariantAlleleFraction": "5.63%"
            },
            {
                "Gene": "IDH1",
                "DNA Alteration": "c.394C>A",
                "GeneMutation": "p.R119Q Nonsense-GOF",
                "VariantAlleleFraction": "3.29%"
            },
            {
                "Gene": "DNMT3A",
                "DNA Alteration": "c.2711C>T",
                "GeneMutation": "p.P904L Nonsense-GOF",
                "VariantAlleleFraction": "9.76%"
            },
            {
                "Gene": "CDKN2A",
                "DNA Alteration": "c.151G>A",
                "GeneMutation": "p.V51D Frameshift-GOF",
                "VariantAlleleFraction": "1.27%"
            },
            {
                "Gene": "H3.3",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G35L Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "9.68%"
            },
            {
                "Gene": "XPC",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.S346P Nonsense-LOF",
                "VariantAlleleFraction": "4.39%"
            },
            {
                "Gene": "MAPK1",
                "DNA Alteration": "c.964G>A",
                "GeneMutation": "p.E322K Nonsense-LOF",
                "VariantAlleleFraction": "6.4%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "PTCH1"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Frameshift-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "1.91%"
            },
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Stopgain-LOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "19.48%"
            },
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": " p.W266* Nonsense-LOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "25.86%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "SMO",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": " p.W266* Nonsense-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "19.68%"
            },
            {
                "Gene": "FLT3",
                "DNA Alteration": "c.2028C>A",
                "GeneMutation": "p.D835X Spliceregionvariant-LOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "18.03%"
            },
            {
                "Gene": "HSD3B1",
                "DNA Alteration": "c.1100C>A",
                "GeneMutation": "p.T367N Nonsense-GOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "10.09%"
            }
        ]
    },
    "clinical history": {
        "Date": "2024-04-06"
    },
    "other": {
        "ReportId": "4528",
        "ReportDate": "2024-04-09",
        "SignedBy": "David Williams",
        "Supervisor": "Dr. David Ayala"
    }
}